ncRNA basic information
ncRNA ID:
MIMAT0004509
ncRNA Database:
miRBase
ncRNA Name:
miR-93-3p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-PCR
ncRNA Target Gene:
SFRP1
ncRNA Pathway:
Wnt/Beta-catenin pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The miRNA array profiles of 1299 breast cancer patients were collected from the Metabric database and subjected to analysis of the altered miRNAs between TNBC and non-TNBC. In Student¡¯s t-test and Kaplan-Meier analysis, four upregulated miRNAs correlated with poor survival in TNBC but not in non-TNBC. Four miRNAs were manipulated in multiple cell lines to investigate their functional role in carcinogenesis. From these results, we studied miR-105 and miR-93-3p in greater detail. The level of miR-105 and miR-93-3p were evaluated in 25 breast cancer tumor tissues. In addition, the diagnostic utility of circulating miR-105 and miR-93-3p were examined in 12 normal and 118 breast cancer plasma samples by ROC curve construction.
Drug Response:
resistant
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line (MCF 10A,MB-361, MCF-7, BT-483, AU565, SkBR3,MB-231,Hs578T, HCC1599, HCC1806, HCC1937, BT-549, DU4475,HCC70,MB-231,293 T )
Other information
Title:
miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Journal:
Breast Cancer Res
Published:
2017
PubMed ID:
29258605